SCHEMBL12468366

SCHEMBL12468366

N[C@@H](c1cc2cccc(Cl)c2nc1-c1cccnc1)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.42
PIK3CG P48736 1/20 0.42
NQO2 P16083 2/20 0.39
ADORA2A P29274 2/20 0.39
ADORA2B P29275 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
PDE4A P27815 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
KDM4E B2RXH2 1/20 0.34
MKNK1 Q9BUB5 2/20 0.34
MKNK2 Q9HBH9 2/20 0.34
MEN1 O00255 1/20 0.34
PSIP1 O75475 1/20 0.34
AXL P30530 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15363619 1.00 PIK3CD (0.42) PIK3CDPIK3CGNQO2ADORA2AADORA2B
SCHEMBL15363745 0.87 PIK3CD (0.41) PIK3CDPIK3CGADORA2ASMN1; SMN2PDE4A
SCHEMBL15363822 0.86 SMN1; SMN2 (0.37) SMN1; SMN2NPC1RAB9AL3MBTL1PDE4A
SCHEMBL15363689 0.86 CYP2A6 (0.42) PIK3CDSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL15363630 0.84 PIK3CD (0.39) PIK3CDPIK3CGADORA2AIRAK4PDE4D
SCHEMBL15363686 0.84 PIK3CD (0.37) PIK3CDPIK3CG
SCHEMBL15363672 0.84 PIK3CD (0.38) PIK3CDPIK3CGSMN1; SMN2KDM4ECYP2A6
SCHEMBL15363595 0.83 PIK3CD (0.46) PIK3CDPIK3CGNPC1RAB9A
SCHEMBL15363612 0.81 CYP2C9 (0.43) L3MBTL1PDE4APDE4CPDE4DCYP2C9
SCHEMBL15363696 0.81 PIK3CD (0.39) PIK3CDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2614061-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2015-05-20 EP disclosed
US-9029392-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2015-05-12 US disclosed
US-20130296338-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2013-11-07 US disclosed
EP-2614061-A1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2013-07-17 EP disclosed
WO-2012032334-A1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296338-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors MAP3K13, MAP4K3, MAP3K3 PIK3CD 339/4885PIK3CG 351/4885NQO2 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.